Keros Therapeutics Inc
KROS
Get informed when a big investor buys or sells
+ FollowMarket Cap$358.06M
Close$
$13.60
17.7% upside
Current Fair Value
17.7% upsideUndervalued by 17.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $358.06 Million |
|---|---|
| Enterprise Value | $116.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.34 |
| Beta | 1.02 |
| Outstanding Shares | 19,800,322 |
Return
| Return on Equity | -31.70% |
|---|---|
| Return on Assets | -28.91% |
| Return on Invested Capital | -39.99% |
Valuation & Multiples
| P/E Ratio | -3.02 |
|---|---|
| PEG | 46.74 |
| Price to Sales | - |
| Price to Book Ratio | 0.89 |
| Enterprise Value to Revenue | 7.74 |
| Enterprise Value to EBIT | -1.05 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.34
Average shareholder expectationRevenue Estimate
$828,571
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$14.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 231.98% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 14,400▼ 92.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.51%▼ 0.22% |
|---|---|
| Total Invested | $200.27M▼ 2.57% |
| Investors Holding | 134▼ 22.00% |
ESG Score
No data